NASDAQ: ITRMIterum Therapeutics PLC Stock Ownership - Who owns Iterum Therapeutics?
Insider buying vs selling
Have Iterum Therapeutics PLC insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.
Be the first to know when ITRM insiders and whales buy or sell their stock.
ITRM Shareholders
What type of owners hold Iterum Therapeutics PLC stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ra Capital Management LP | 29.13% | 11,651,597 | $11.55M | Insider |
| Brenton Karl Ahrens | 4.33% | 1,733,580 | $1.72M | Insider |
| Canaan X LP | 4.33% | 1,733,170 | $1.72M | Insider |
| James Healy | 4.33% | 1,732,668 | $1.72M | Insider |
| Patrick J. Heron | 3.87% | 1,547,322 | $1.53M | Insider |
| Vijay K. Lathi | 3.64% | 1,456,303 | $1.44M | Insider |
| Sofinnova Venture Partners IX LP | 3.07% | 1,226,514 | $1.22M | Insider |
| Shahzad Malik | 2.17% | 868,161 | $860.35k | Insider |
| Ronald Hunt | 0.90% | 359,366 | $356.13k | Insider |
| New Leaf Venture Partners LLC | 0.86% | 345,020 | $341.91k | Institution |
ITRM vs Biotech Stocks
Iterum Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.